The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: A retrospective analysis of enrolled cases in Japan

2008 ◽  
Vol 51 (2) ◽  
pp. 188-192 ◽  
Author(s):  
Naoto Fujita ◽  
Tetsuya Mori ◽  
Tetsuo Mitsui ◽  
Hiroko Inada ◽  
Keizo Horibe ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Retrospective Analysis ◽  
Cell Leukemia ◽  
Hematopoietic Stem ◽  
Non Hodgkin Lymphoma ◽  
B Cell Leukemia

scholarly journals The Role of MYC and BCL-2 Double Expression the in DLBCL Patients with Advanced Stage and Elevated LDH Who Received Upfront ASCT after R-CHOP

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4219-4219
Author(s):  
Yu Ri Kim ◽  
Sun Och Yoon ◽  
Soo-Jeong Kim ◽  
June-Won Cheong ◽  
Hyewon Lee ◽  
...  
Keyword(s):  
Overall Survival ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Hematopoietic Stem Cell ◽  
Germinal Center ◽  
Hematopoietic Stem ◽  
Germinal Center B Cell

Abstract Diffuse large B-cell lymphoma (DLBCL) with MYC and BCL2 protein concurrent expression, double- expressor lymphoma (DEL), by immunohistochemistry (IHC) was related with poor prognosis. To investigate the role of upfront autologous hematopoietic stem cell transplantation (ASCT) in double-expresser lymphoma, we retrospectively evaluated 44 DLBCL patients with advanced stage and elevated LDH who received upfront ASCT. We used the cut off value of BCL2 was 50% and c-MYC was 40%. All patients were treated with frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy. Median age of 44 patients was 52.0 years (range, 23 ~ 64 years). Two-year overall survival (OS) was 83.3% and progression free survival (PFS) was 76.6%. Double-expressor lymphoma (DEL) were detected 14 patients (31.8%). Two-year OS of the patients with DEL was 77.4%, non-DEL was 86.6%. Two-year PFS of the patients with DEL was 77.9% and non-DEL was 80.9%. Eleven (25.0%) patients were germinal center B-cell (GCB) subtype and 33 (75.0%) patients were non-GCB subtype. There was no survival difference between GCB and non-GCB subtype (Figure 1A, 1B). In the patients with GCB subtype, 2 (18.2%) patients were classified to DEL. OS and PFS were not different according to DEL. Among non-GCB subtype, the patients with DEL (n=12) showed the comparable OS and PFS compared to the patient with non-DEL (n=21). Two-year OS of DEL patients was 73.3%, non-DEL was 90.9%. Two-year PFS of DEL patients was 74.1 %, non-DEL was 82.6 (Figure 2A. 2B). In conclusion, MYC and BCL2 concurrent expression did not show the poor outcome among the high risk DLBCL patients treated with upfront ASCT regardless of molecular classification. It will be need to investigate the role of ASCT in these group of patients. Figure 1 Kaplan-Meier analysis of overall survival and progression survival in germinal center B-cell subtype versus non-germinal center B-cells subtype Figure 1. Kaplan-Meier analysis of overall survival and progression survival in germinal center B-cell subtype versus non-germinal center B-cells subtype Figure 2 Overall survival and progression survival of patients treated with upfront autologous hematopoietic stem cell transplantation according to the presence of double expression Figure 2. Overall survival and progression survival of patients treated with upfront autologous hematopoietic stem cell transplantation according to the presence of double expression Disclosures No relevant conflicts of interest to declare.

scholarly journals Modified Conditioning Regimen with Idarubicin Prior to Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5349-5349
Author(s):  
Chen Tian ◽  
Yueyang Li ◽  
M. James You ◽  
Zhigang Zhao ◽  
Yizhuo Zhang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Hematopoietic Stem Cell ◽  
Adverse Reactions ◽  
Conditioning Regimen ◽  
Hematopoietic Stem ◽  
Non Hodgkin Lymphoma

High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) has become a standard consolidation treatment for patients with invasive lymphoma. The combination of cyclophosphamide, carmustine, and etoposide (CBV) is a commonly used conditioning regimen prior to auto-HSCT for patients with invasive lymphoma. Many modifications of the CBV regimen, including the addition of idarubicin, have been employed, with varying results. We retrospectively analyzed the clinical characteristics and treatment outcomes of 36 patients with invasive B-cell non-Hodgkin lymphoma treated with a conditioning regimen prior to auto-HSCT between January 2015 and June 2018. For our analysis, the patients were divided into two groups: one group received the classic CBV conditioning regimen and the other group received idarubicin at a dose of 8 mg/m2 for 3 days in addition to the CBV regimen. Overall survival (OS), median progression-free survival (PFS), adverse reactions, and hematopoietic reconstitution time were compared between the two groups. OS and PFS were analyzed using the Kaplan-Meier method, and the log-rank test was used for comparison between groups. Cox regression was used for multivariable analysis of other clinical factors. The median follow-up time was 29 months. Among the 36 patients in the cohort, 19 were male and 17 were female, with a male-to-female ratio of 1.12 to 1. The median age of onset was 39.5 years; 18 patients were older than 40 years and 18 were younger than 40 years. Twenty-six patients (72%) had an international prognostic index score of 0-2 and 10 patients (28%) had a score of 3-5. According to Ann Arbor staging criteria, 9 patients (25%) had stage I-II disease and 27 patients (75%) had stage III-IV disease. A total of 21 patients achieved complete remission and 15 patients achieved partial remission before transplantation. There were no significant differences between the groups in terms of neutrophil counts (P = 0.795) or platelet reconstitution time (P = 0.551). Also, there was no difference in adverse reactions between the two groups, suggesting that the addition of idarubicin to the conditioning regimen did not aggravate adverse reactions. OS and PFS were significantly longer in the idarubicin group than among patients who did not receive idarubicin. In the multivariable analysis, the use of idarubicin and complete remission state before auto-HSCT were associated with improved prognosis. These results indicate that the use of idarubicin with the CBV conditioning regimen prior to auto-HSCT is a safe and effective choice for patients with invasive B-cell non-Hodgkin lymphoma. Keywords: B-cell non-Hodgkin lymphoma; conditioning regimen; autologous hematopoietic stem cell transplantation; idarubicin Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document